Published Online
on June 26, 2006

A more recent version of this article appeared on August 1, 2006

This Article Full Text (PDF) All Versions of this Article: 48/2/246    most recent 01.HYP.0000232179.60442.84v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by White, W. B. Articles by Pitt, B. Search for Related Content PubMed PubMed Citation Articles by White, W. B. Articles by Pitt, B. Related Collections Clinical Studies Other hypertension Other Treatment Related Article

Submitted on March 20, 2006
Revised on April 6, 2006

Effects of a New Hormone Therapy, Drospirenone and 17--Estradiol, in Postmenopausal Women With Hypertension

William B. White^*; Vladimir Hanes; Vijay Chauhan; and Bertram Pitt

From the Division of Hypertension and Clinical Pharmacology (W.B.W.), The Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington; Research and Development (V.H., V.C.), Berlex, Inc, Montville, NJ; Division of Cardiology (B.P.), University of Michigan Medical School, Ann Arbor.

^* To whom correspondence should be addressed. E-mail: wwhite{at}nso1.uchc.edu.

Abstract--Drospirenone (DRSP), a progestin with antialdosterone activity, has been developed for hormone therapy in combination with 17--estradiol (E2) in postmenopausal women. We evaluated the antihypertensive efficacy and safety of various doses of DRSP and E2 and estradiol alone in postmenopausal women with hypertension using ambulatory and clinic blood pressure (BP) monitoring. This was a randomized, double-blind clinical trial of 3 doses of DRSP combined with estradiol, estradiol alone, and placebo in 750 postmenopausal women with stage 1 to 2 hypertension between 45 to 75 years. Ambulatory and clinic BPs, potassium, aldosterone, and lipid measurements and adverse events were evaluated in postmenopausal women with stages 1 to 2 hypertension during 8 weeks of double-blind therapy. DRSP and E2 induced dose-related reductions in the ambulatory and clinic systolic BP with physiological increases in serum aldosterone. Significant decreases in 24-hour systolic pressure were observed at doses of 2 and 3 mg of DRSP combined with estradiol but not by estradiol alone or 1 mg of DRSP with estradiol. There were no significant changes from baseline in potassium in any treatment group. Small, significant reductions in total and low-density lipoprotein cholesterol occurred on all of the active treatments, and serum triglycerides did not change. Adverse event rates were low and similar across treatment groups. In conclusion, these data show that DRSP combined with E2 significantly reduces BP in postmenopausal women with hypertension and did not induce significant increases in serum potassium. These characteristics may lead to a new benefit for this novel hormone therapy in postmenopausal women with hypertension.

Key words: drospirenone • hormones • aldosterone • blood pressure • hypertension, renal

Related Article:

Drospirenone: An Antihypertensive in Waiting

Domenic A. Sica
Hypertension 2006 48: 205-206. [Full Text] [PDF]

This article has been cited by other articles:

				A. H. Karara, V. Hanes, A. Alonso, P. Ni, N. Poola, R. Silang, H. Blode, and R. A. Preston Pharmacokinetics and Pharmacodynamics of Drospirenone-Estradiol Combination Hormone Therapy Product Coadministered With Hydrochlorothiazide in Hypertensive Postmenopausal Women J. Clin. Pharmacol., October 1, 2007; 47(10): 1292 - 1302. [Abstract] [Full Text] [PDF]

				T. Simoncini, X-D. Fu, A. Caruso, S. Garibaldi, C. Baldacci, M.S. Giretti, P. Mannella, M.I. Flamini, A.M. Sanchez, and A.R. Genazzani Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors Hum. Reprod., August 1, 2007; 22(8): 2325 - 2334. [Abstract] [Full Text] [PDF]

				Angeliq for Treatment of Menopausal Symptoms Obstet. Gynecol., July 1, 2007; 110(1): 177 - 178. [Full Text] [PDF]

				K. Tsuda A New Hormone Therapy With Drospirenone and NO Production in Postmenopausal Women Hypertension, November 1, 2006; 48(5): e106 - e106. [Full Text] [PDF]

				W. B. White Response to a New Hormone Therapy With Drospirenone and NO Production in Postmenopausal Women Hypertension, November 1, 2006; 48(5): e107 - e107. [Full Text] [PDF]

				Can a Hormone Therapy Combat Hypertension? Journal Watch Women's Health, August 31, 2006; 2006(831): 3 - 3. [Full Text]

				D. A. Sica Drospirenone: An Antihypertensive in Waiting Hypertension, August 1, 2006; 48(2): 205 - 206. [Full Text] [PDF]